Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Notes Payables (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 5 years of Notes Payables data on record, last reported at $702184.0 in Q1 2025.

  • For Q1 2025, Notes Payables rose 42.42% year-over-year to $702184.0; the TTM value through Mar 2025 reached $702184.0, up 42.42%, while the annual FY2025 figure was $702184.0, 42.42% up from the prior year.
  • Notes Payables reached $702184.0 in Q1 2025 per SXTC's latest filing, up from $493054.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $702184.0 in Q1 2025 and bottomed at $167453.0 in Q1 2023.
  • Average Notes Payables over 3 years is $454230.3, with a median of $493054.0 recorded in 2024.
  • Peak YoY movement for Notes Payables: soared 194.44% in 2024, then skyrocketed 42.42% in 2025.
  • A 3-year view of Notes Payables shows it stood at $167453.0 in 2023, then skyrocketed by 194.44% to $493054.0 in 2024, then surged by 42.42% to $702184.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $702184.0 in Q1 2025, $493054.0 in Q1 2024, and $167453.0 in Q1 2023.